TC
DMAC icon

Truvestments Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Truvestments Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.7K Hold
9,849
– – 0.01% 460
2025
Q4 		$78.4K Buy
9,849
+5,210
+112% +$39K 0.01% 381
2025
Q3 		$31.9K Buy
4,639
+627
+16% +$3.4K 0.01% 512
2025
Q2 		$15.6K Buy
+4,012
New +$15.6K ﹤0.01% 581

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Truvestments Capital's DMAC Position: Q1 2026 in Review

Truvestments Capital held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 9,849 shares worth $66.7K. The position accounts for 0.01% of the portfolio, ranked #460.

Truvestments Capital first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. The position peaked at $78.4K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Truvestments Capital held 9,849 shares of DiaMedica Therapeutics worth $66.7K as of Q1 2026.
  • Truvestments Capital left its DiaMedica Therapeutics share count unchanged in Q1 2026.
  • DiaMedica Therapeutics made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #460 holding.
  • Truvestments Capital first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Truvestments Capital's DiaMedica Therapeutics position peaked at $78.4K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.